Hepatitis B Virus X Protein Stabilizes Cyclin D1 and Increases Cyclin D1 Nuclear Accumulation through ERK-Mediated Inactivation of GSK-3β

Abstract

The Hepatitis B virus X protein (HBx) contributes centrally to the pathogenesis of hepatocellular carcinoma (HCC). It has been suggested that the transcriptional activation of cyclin D1 by HBx is implicated in the development of HCC. However, numerous studies have shown that overexpression of cyclin D1 alone is not sufficient to drive oncogenic transformation. Herein, we investigated whether HBx can stabilize cyclin D1 and induce cyclin D1 protein nuclear accumulation, and thereby accelerate hepatocarcinogenesis. The effects of HBx on cyclin D1 stabilization were assessed in cell-based transfection, Western blot, immunoprecipitation, immunocytofluorescence staining, and flow-cytometric assays. The results demonstrated that ectopic expression of HBx in HCC cells could extend the half-life of cyclin D1 protein from 40-60 minutes to 80-110 minutes. HBx stabilized cyclin D1 primarily in the S phase of the cell cycle, in a manner dependent on the inactivation of GSK-3b, which was mediated by ERK activation. HBx also prompted the nuclear accumulation of cyclin D1, and cotransfection of the constitutively active mutant of GSK-3b along with HBx could reverse the nuclear accumulation and subsequent cell proliferation induced by HBx. Further, a positive correlation between HBx and nuclear cyclin D1 level was established in HCC specimens detected by an immunohistochemical assay. Taken together, our results indicated that HBx could stabilize and increase cyclin D1 nuclear accumulation through ERK-mediated inactivation of GSK-3b. This HBx-induced cyclin D1 upregulation might play an important role in HCC development and progression. Cancer Prev Res; 8(5); 455-63. Ó2015 AACR.

Eukaryotic Translation Initiation Factor 3b is both a Promising Prognostic Biomarker and a Potential Therapeutic Target for Patients with Clear Cell Renal Cell Carcinoma

“…The serine/threonine kinase Akt (also termed protein kinase B or PKB) has attracted a great deal of attention because Akt plays critical roles in the regulation of many cellular functions including metabolism, growth, proliferation, survival, transcription, and protein synthesis 25 - 29 . We found that eIF3b depletion was not associated with any significant change in Akt levels; however, the level of the activated form, p-Akt, fell in parallel with the extent of eIF3b depletion, indicating that the Akt signaling pathway was involved in such depletion.…”

Long noncoding RNA UCA1 induced by SP1 promotes cell proliferation via recruiting EZH2 and activating AKT pathway in gastric cancer

“…20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 Moreover, AKT/GSK-3B/cyclin D1 axis was the classic pathway involved in modulation of cyclin D1 in cancer cell. 35, 36 Furthermore, EZH2 and AKT could influence expression of each other indicating that they constituted a positive loop. 21, 37, 38, 39 In addition, one-fifth of all human lncRNAs identified is physically associated with EZH2.…”

Ligand activation of peroxisome proliferator-activated receptor-β/δ suppresses liver tumorigenesis in hepatitis B transgenic mice

“…CYCLIN D1 regulates the G1/S phase transition during cell cycle (Resnitzky et al 1994) and can promote hepatocyte proliferation in the absence of a mitogen (Albrecht and Hansen 1999). CYCLIN D1 is also frequently over-expressed in liver tumor models and can contribute to the progression of hepatitis-induced hepatocellular carcinoma (Chen et al 2015; Masaki et al 2003; Nishida et al 1994). c-MYC, which is often over-expressed in liver cancer (Jang et al 2012; Kawate et al 1999), can also inhibit termination of differentiation, and promote hepatocyte proliferation, angiogenesis and cellular transformation, all of which can contribute to tumor promotion (Meyer and Penn 2008).…”